Drug intelligence / Profile preview

LpD64

Development stage: Discontinued
Lead developer: Valbiotis
Administration: Oral

Overview

**LpD64** is a discontinued Valbiotis plant-extract complex, also referred to as LIPIDRIVE, developed as an oral nutritional intervention for overweight and obesity. It was derived from a blend of plants and evaluated in preclinical obesity models and a Phase I/II study in people with obesity. Reported preclinical effects included reduced body-weight gain and fat mass, improved glucose and insulin-related measures, and changes in gut-microbiota composition; however, no defined active constituents or discrete molecular target have been publicly disclosed. Valbiotis discontinued the obesity program in 2020 as part of a pipeline update. ([marketscreener.com](https://www.marketscreener.com/quote/stock/VALBIOTIS-34897103/news/LIPIDRIVE-efficacy-confirmed-in-three-models-finalization-of-recruitment-for-Phase-I-II-in-human-25291498/))

Other names: LIPIDRIVE

Beyond the preview

Go deeper on LpD64.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LpD64.

Explore the full profile